Ohad Yosefson

Skills

THERAPEUTIC AREA & MODALITY BREADTH
Therapeutic areas: Cross-TA breadth: Oncology (Wnt/β-catenin, peptide-MHC, TCR-antigen) • Immunology & autoimmunity (Crohn's, TL1A class, IgA nephropathy) • Rare disease (FAP/desmoid evaluation, IgE allergy) • Metabolic disease (GLP-1 / GIP / glucagon multi-agonists) • Infectious disease & AMR
Modalities: Peptide therapeutics • Protein biologics & Fc-fusions • Antibodies & nanobodies • Engineered enzymes / directed evolution • AI/ML-enabled discovery platforms • Bispecifics (analytical coverage)

About

I evaluate biopharma science and strategy to inform high-stakes R&D and partnering decisions.

The through-line across 15+ years: rigorously assessing what will work — before the capital is committed.

CAREER

→ MIT — PhD Biochemistry & postdoc
→ Repertoire Immune Medicines — Employee #4
→ Resonance Medicine — scientific leadership
→ Metaphore Biotechnologies — scientific leadership
→ RevAMP Therapeutics — Founder

Across immune medicines, metabolic disease, and computational platform biotech.
Deep technical grounding in protein engineering, enzymology, peptide therapeutics, and cell-free systems.

WHAT I DO

I'm focused on Search & Evaluation / Business Development — where scientific judgment is the core of the job:

→ Scientific and technical due diligence
→ Competitive landscape assessment
→ Asset prioritization and go / no-go evaluation

Having built a company, raised against a platform invention, and led partnership discussions from the asset side, I bring both an operator's and a founder's perspective to evaluating external opportunities.

SELECTED CREDENTIALS

→ 6 patents
→ 10 peer-reviewed publications (Nat Struct Mol Biol, Nat Chem Biol, Cell Reports, Sci Adv)
→ Cell-free synthesis invention that supported a $30M Series A
→ PhD Biochemistry, MIT · MIT postdoc

📍 Greater Boston